Peptimes

Track P21 in Peptimes

P21 (P021) is a small synthetic peptide compound: N-acetyl-Asp-Gly-Gly-Leu joined to an adamantylated glycine (Ac-DGGL(A)G-NH2), with the formula C27H42N6O8. (Source: FDA's substance registry (GSRS).)

Is P21 FDA-approved?

No. P21 isn't FDA-approved, and Drugs@FDA lists no application with it as an active ingredient.

Checked 1 Nov 2026. The sources are below.

P21

Also: P021, Peptide 021, Ac-DGGL(A)G-NH2

Status label in the Peptimes Library
Not FDA-Approved
Routes in Peptimes
SubcutaneousIntramuscularOralSublingualNasalTopicalOther
Updated
1 Nov 2026

US regulatory status

  • FDA status

    Not FDA-Approved. Drugs@FDA lists no application with P21 (P021) as an active ingredient.

    Source: Drugs@FDA, checked 1 Nov 2026

What studies have looked at

Each point says who or what was studied and what the study reported, with its source and the date we checked it. These are findings from the sources cited, not advice or a promise of any result.

  • In animals or the lab

    In female 3xTg-AD mice, a mouse model of Alzheimer's disease, P021 reduced abnormal tau hyperphosphorylation and soluble amyloid-beta (plaque load only trended lower). The authors report that it rescued deficits in cognition, new nerve-cell formation and synaptic plasticity.

    Source: PMID 25046994, checked 1 Nov 2026

  • In animals or the lab

    In 3xTg-AD mice treated from before plaques or tangles appeared, P021 rescued dendritic and synaptic deficits, boosted new nerve-cell formation and reversed cognitive impairment, the authors report.

    Source: PMID 28655344, checked 1 Nov 2026

  • In animals or the lab

    In a human cell model of CDKL5 deficiency disorder, P021 restored nerve-cell growth, survival and maturation. In Cdkl5 knockout mice it did not raise BDNF levels or improve brain structure, and gave limited behavioural benefit.

    Source: PMID 39592934, checked 1 Nov 2026

How to track it in Peptimes

Add P21 in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Not FDA-Approved”.

  • Routes: the app lets you record whichever route you used; none is established. Its routes are subcutaneous, intramuscular, oral, sublingual, nasal, topical and Other.
  • Logging: the amount you took, the route and how you feel.
  • Injection sites: subcutaneous and intramuscular doses record the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next. Other routes skip this step.
  • Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.

Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell P21 or any other compound.

More sources

  • FDA, Global Substance Registration System, P-21, checked 1 Nov 2026: its structure and formula, and the names P021 and P21.
  • NLM, MeSH, P021 peptide, checked 1 Nov 2026: described as a neurotrophic peptidergic compound.
  • Baazaoui and Iqbal, 2017, PMID 28655344, checked 1 Nov 2026: the developers describe P021 (Peptide 021) as derived from a region of ciliary neurotrophic factor (CNTF).
  • ClinicalTrials.gov, searched 1 Nov 2026: no registered study of P021.

Peptide tracker appInjection-site history in PeptimesWhat FDA status terms mean

Coming soon to the App Store

Coming soon to Google Play

See planned pricing